



## Charles River Laboratories Focuses on the Future of Oncology at AACR Annual Meeting 2018

April 10, 2018

WILMINGTON, Mass.--(BUSINESS WIRE)--Apr. 10, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of oncology experts is presenting 13 scientific posters, both independently and collaboratively with clients, and will highlight an enhanced oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting. The meeting is taking place from April 14-18, 2018, at McCormick Place in Chicago, Illinois.

### Showcasing Scientific Excellence

Throughout the meeting, Charles River's experts will present the Company's industry-leading oncology capabilities and highlight the latest advancements by presenting innovative applications for CRISPR/Cas9, immuno-oncology, *in vitro* assays, and more.

Noteworthy posters include:

- **Determination of signal transduction pathway activity in patient-derived xenograft models in comparison with clinical patient tumor samples for a variety of human cancer types (Presented: Monday, April 16, 8:00 a.m.-12:00 p.m.)** This project, completed with Philips Molecular Pathway Diagnostics, describes an analysis method which identifies and quantifies activity in the cell signaling pathways of Charles River's patient-derived xenograft (PDX) tumor models.
- **A translational platform using primary human immune cells *in vitro*, syngeneic and humanized models *in vivo* to support and advance immuno-oncology drug discovery (Presented: Monday, April 16, 8:00 a.m.-12:00 p.m.)** Researchers established a translational immuno-oncology platform with the capability of progressing biologics or small-molecule modulators of immune response from *in vitro* and *ex vivo* through *in vivo* assays, including humanized models.
- **Quantitative measurement of immune-modulatory mediators within tumors of freely moving mice utilizing *in vivo* microdialysis (Presented: Tuesday, April 17, 8:00 a.m.-12:00 p.m.)** Leveraging microdialysis in tumors, researchers monitored changes in biochemical elements within tumors to better understand cancer biology in the development of novel therapies.

A full schedule of Charles River's activities during AACR 2018 is available [online](#). Reprints of each poster will be available in Booth #1615 during the conference and Charles River experts [will be available](#) for meetings to discuss how an integrated approach can support drug discovery and development programs from hit ID to IND. Throughout the conference, Charles River will be providing live updates on the [Eureka Blog](#), including reviews of scientific sessions and input on the research being presented.

### Bioinformatic Additions to Compendium

In [February 2018](#), Charles River announced the launch of its new online [Tumor Model Compendium](#) web interface. The new Compendium interface provides oncology researchers with an easily accessible, user-friendly resource to identify tumor models based on specific molecular and histological properties, accompanied by selected patient information. Ahead of AACR, Charles River will incorporate the signal transduction pathway activity, developed with [Philips Molecular Pathway Diagnostics](#), as a characteristic of Charles River's PDX models. The resemblance of these pathways to clinical samples will lead to better development and clinical application of targeted drugs for personalized cancer treatment.

### Select Humanization Kit

[Recently](#), Charles River and HemaCare Corporation (OTCBB: HEMA) formed a strategic partnership to advance human immune system research by developing a more efficient and reliable method of working with humanized mice. Through the partnership, HemaCare's peripheral blood mononuclear cells (PBMCs) are paired with Charles River's NCG triple immunodeficient mouse. This [NCG/PBMC Select Humanization Kit](#) is the first of its kind in the industry and provides both the NCG mouse and vials of prescreened human PBMCs, allowing researchers to efficiently develop humanized mouse models on their own timeline.

### Approved Quotes

- "Our scientists are exploring groundbreaking applications of innovative tools and technologies across oncology research. From CRISPR to *in vitro* immuno-oncology to microdialysis, our deep scientific bench affords us a unique opportunity to leverage learnings from different therapeutic areas and apply them to oncology. We're proud to showcase our body of work at AACR this year." --Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Charles River
- "The continued expansion of our Tumor Model Compendium highlights the significant role bioinformatics plays in oncology research. Scientists require data to conduct their research efficiently and effectively. Our Compendium puts the power of our data in their hands—eliminating steps and driving the development process forward." --Aidan Synnott, Executive Director, Discovery Oncology, Charles River

### About the American Association for Cancer Research

The mission of the [American Association for Cancer Research](#) is to prevent and cure cancer through research, education, communication, and

collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

#### **About Charles River**

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit [www.criver.com](http://www.criver.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180410005475/en/>

Source: Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

**Investor Contact:**

Susan E. Hardy, 781-222-6190

Corporate Vice President, Investor Relations

[susan.hardy@crl.com](mailto:susan.hardy@crl.com)

or

**Media Contact:**

Amy Cianciaruso, 781-222-6168

Corporate Vice President, Public Relations

[amy.cianciaruso@crl.com](mailto:amy.cianciaruso@crl.com)